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773A Pooled Analysis of Multicenter Cohort Studies of
123I-mIBG Imaging of Sympathetic Innervation for
Assessment of Long-Term Prognosis in Heart FailureOBJECTIVES The study objectives were to create a cardiac metaiodobenzylguanidine (mIBG) database using
multiple prospective cohort studies and to determine the quantitative iodine-123–labeled mIBG indices for
identifying patients with chronic heart failure (HF) at greatest and lowest risk of lethal events.
BACKGROUND Although the prognostic value of cardiac mIBG imaging in patients with HF has been
shown, clinical use of this procedure has been limited. It is required to deﬁne universally accepted
quantitative thresholds for high and low risk that could be used as an aid to therapeutic decision-making
using a large cohort database.
METHODS Six prospective HF cohort studies were updated, and the individual datasets were combined for the
present patient-level analysis. The database consisted of 1,322 patients with HF followed up for a mean interval of 78
months. Heart-to-mediastinum ratio (HMR) and washout rate of cardiac mIBG activity were the primary cardiac
innervation markers. The primary outcome analyzed was all-cause death.
RESULTS Lethal events were observed in 326 patients, and the population mortality rate was 5.6%, 11.3%, and
19.7% at 1, 2, and 5 years, respectively. Multivariate Cox proportional hazard model analysis for all-cause mortality
identiﬁed age (p < 0.0001), New York Heart Association (NYHA) functional class (p < 0.0001), late HMR of cardiac
mIBG activity (p < 0.0001), and left ventricular ejection fraction (LVEF) (p ¼ 0.0029) as signiﬁcant independent
predictors. Analysis of the 512-patient subpopulation with B-type natriuretic peptide (BNP) results showed BNP
(p < 0.0001), greater NYHA functional class (p ¼ 0.0002), and late HMR (p ¼ 0.0011) as signiﬁcant predictors,
but LVEF was not. The receiver-operating characteristic–determined threshold of HMR (1.68) identiﬁed patients
at signiﬁcantly increased risk in any LVEF category. Survival rates decreased progressively with decreasing
HMR, with 5-year all-cause mortality rates >7% annually for HMR <1.25, and <2% annually for HMR $1.95.
Addition of HMR to clinical information resulted in a signiﬁcant net reclassiﬁcation improvement of 0.175 (p <
0.0001).
CONCLUSIONS Pooled analyses of independent cohort studies conﬁrmed the long-term prognostic value
of cardiac mIBG uptake in patients with HF independently of other markers, such as NYHA functional class, BNP,
and LVEF, and demonstrated that categoric assessments could be used to deﬁne meaningful thresholds for
lethal event risk. (J Am Coll Cardiol Img 2013;6:772–84) ª 2013 by the American College of Cardiology
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BNP = B-type natriuretic pe
HF = heart failure
HMR = heart-to-mediastinu
ratio
I = iodine
ICD = implantable cardiove
deﬁbrillator
LVEF = left ventricular
ejection fraction
mIBG =
metaiodobenzylguanidine
NE = norepinephrine
NRI = net reclassiﬁcation
improvement
NYHA = New York
Heart Association
ROC = receiver-operating
characteristic
VT = ventricular tachycard
WR = washout rate
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774espite recent advances in pharmacological
and nonpharmacological treatment of
heart failure (HF), the physiological char-
acteristics that determine the risk proﬁle of
an individual patient are often poorly understood.
One attribute of cardiac physiology that could have
direct application to therapeutic measures used to
reduce occurrence of lethal events in patients with
HF is the status of the autonomic nervous system.
Autonomic nervous system function is associated
with manifestations, progression, and outcomes
of chronic HF (1). Despite initial compensatory
augmentation for maintenance of systemic hemo-
dynamics and peripheral circulation, long-lasting
and excess stimulation of sympathetic nerveptide
m
rter-
iafunction is responsible for adverse events
in HF attributable to increased activity of
the renin-angiotensin-aldosterone system
(2,3). This adrenergic hyperactivity results
in increases in tissue oxygen demand, pe-
ripheral vascular resistance, plasma volume
and oxygen stress, and water–electrolyte
imbalance. Other potential consequences of
this hyperactivity are myocardial ischemia
and arrhythmic events.
Persistent efferent stimulation of sym-
pathetic nerve function in failing hearts
impairs efﬁciency of reuptake, turnover,
and storage of norepinephrine (NE) at
pre-synaptic nerve endings, resulting in
increased spill-over and deﬁciency of NE
stores (4). Cardiac sympathetic function
and status of innervation can be assessed
noninvasively using neuroimaging with
the NE analog, iodine (I)-123–labeled
metaiodobenzylguanidine (mIBG), which
shares uptake, storage, and release system
at nerve endings with NE (5). IncreasedNE turnover and pre-synaptic NE deﬁcits can be
identiﬁed as an increased mIBG washout rate (WR)
from the heart and decreased mIBG activity quan-
tiﬁed as the heart-to-mediastinum ratio (HMR).
Over the past 2 decades, numerous single and
multicenter studies (6–11) and a recent meta-
analysis using published data (12) have demon-
strated the efﬁcacy of cardiac mIBG sympathetic
imaging for identifying symptomatic patients with
HF most likely to experience lethal events. How-
ever, these studies have not provided data sufﬁcient
to establish long-term prognostic values and uni-
versally accepted levels of uptake that deﬁne high-
and low-risk patient cohorts. Such deﬁnitions would
require analyses of a large cohort database including
prognostic mIBG markers and other standardclinical variables assessed for HF risk stratiﬁcation.
The present study was designed to create such a
cardiac mIBG database by combining patient-level
data from multiple prospective HF cohort studies
(8,13–19), all of which were performed as
physician-initiated clinical research in routine car-
diology practice in Japan. The objective was to
prospectively analyze the database to conﬁrm short-
and long-term prognostic values of quantitative
123I-mIBG indices on myocardial sympathetic
innervation imaging and then deﬁne uptake levels
that identiﬁed patients with HF at highest and
lowest risk of all-cause mortality.
METHODS
Study design. The present study was designed as a
patient-level analysis combining individual pro-
spectively obtained original datasets from multiple
prospective HF cohorts studied independently be-
tween 1990 and 2009 in Japan (8,13–19). All pa-
tients were participants enrolled in prospective
observational studies of mIBG cardiac imaging, a
procedure that is approved for clinical use in Japan.
The entry criteria for the current analyses were as
follows: a prospective HF follow-up study; estab-
lishment of the HF diagnosis by cardiologists using
standard diagnostic criteria (the Framingham cri-
teria); a minimum of 12 months of periodic follow-
up for patients who survived; a primary end-point
of all-cause mortality; and cardiac mIBG imaging
performed after stabilization using contemporary
drug therapy for the measurement ofHMR andWR.
In the present study, only deﬁnitively conﬁrmed
deaths were considered events, but not aborted
events such as recovery from resuscitated cardiac
arrest or appropriate implantable cardioverter-
deﬁbrillator (ICD) shock.
Cardiac mIBG imaging is a routinely available
clinical procedure in Japan (cost covered by the
national medical insurance system of Japan) that is
recommended in nuclear cardiology practice guide-
lines for the management and prognostic assessment
of HF (20). Standard imaging procedures per-
formed in Japan are as follows: use of 111 MBq of
123I-mIBG with a high speciﬁc activity (commer-
cially available in Japan), a gamma camera equipped
with a low-energy collimator, and early and delayed
imaging, from which HMR and WR are calculated
at the time of imaging.
Follow-up protocol. According to guidelines of the
ethics committee of each medical center, patient
informed consent for participation was obtained in
all original cohorts studied. Performance of the
Table 1. Comparison of Clinical Data Between Survivors and
Nonsurvivors
Survived
(n [ 996)
Dead
(n [ 326) p Value
Age, yrs 60  14 64  12 <0.001
Men 70.1 75.2 0.0074
NYHA functional class <0.0001
I 30 15
II 42 33
III 25 40
IV 3 12
LVEF, % 38  14 33  14 <0.0001
Ischemic cause of HF 27.4 27.3 0.969
Prior myocardial infarction 19.9 21.1 0.658
Diabetes mellitus 22.7 27.1 0.116
Hypertension 33.1 24.8 0.0065
Dyslipidemia 27.1 17.4 0.0090
Sustained ventricular
tachycardia history
21.6 35.3 <0.0001
Brain natriuretic peptide,
pg/ml*
300  366 584  494 <0.0001
Cardiac mIBG study
HMR (late)z 1.80  0.35 1.59  0.29 <0.0001
WR, % 37.5  13.9 44.2  14.6 <0.0001
Medications
Diuretics 65.3 83.1 <0.0001
ACE-I and/or ARB 65.5 64.1 0.657
Beta-blockers 55.1 48.8 0.0458
Aldosterone antagonistsy 47.8 46.3 0.757
Values are mean  SD or %. *n ¼ 512. yn ¼ 539. zHMR (late) indicates HMR
which is obtained from late mIBG scan and equal to late HMR.
ACE-I ¼ angiotensin-converting enzyme-inhibitor; ARB ¼ angiotensin-
receptor blocker; HF ¼ heart failure; HMR ¼ heart-to-mediastinum ratio;
LVEF ¼ left ventricular ejection fraction; mIBG ¼ metaiodobenzylguanidine;
NS ¼ not signiﬁcant; NYHA ¼ New York Heart Association; WR ¼ washout
rate.
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 6 , N O . 7 , 2 0 1 3 Nakata et al.
J U L Y 2 0 1 3 : 7 7 2 – 8 4 Prognosis and Cardiac Sympathetic Activity in HF
775present study also was based on ethical committee
guidelines for approval to collect data and personal
intelligence protection.
Patients with HF from 6 Japanese medical centers
provided data for this study. All patients were
regularly followed for the mean follow-up interval of
77.6 (range 1 to 175) months with a median interval
of 67 months at the outpatient clinic of each facility
by cardiologists who were in charge of HF man-
agement. Median follow-up intervals in the 6 in-
stitutions were 72.0 (range 1 to 175), 73.0 (range 1
to 115), 58.7 (range 9.5 to 91), 83.1 (range 1.6 to
175), 127 (range 1 to 173), and 31.5 (range 10 to 72)
months. The primary endpoint was all-cause death,
including cardiac deaths (pump failure death, death
due to myocardial infarction, and sudden cardiac
death) and noncardiac death. Sudden cardiac death
was deﬁned as witnessed cardiac arrest and death
within 1 h after onset of acute symptoms or unex-
pected death in patients known to have been well
within the previous 24 h. Follow-up data collected
as part of the original studies were updated when
possible. Clinical outcomes were conﬁrmed regularly
by patient medical records or telephone interview
in each facility; therefore, follow-up data were
available for all patients included in this study.
Patients. A total of 1,360 patients were entered into
the original cohort studies, but 32 patients (2.35%)
were excluded from the database because they were
lost to follow-up thereafter. Data from 1,401 mIBG
studies in the remaining 1,328 patients were sub-
mitted for this study. Six surviving patients were
excluded because of a follow-up period <1 year, and
results from 73 repeated (not ﬁrst) mIBG studies
also were removed from the analysis. Thus, the
database for ﬁnal analysis consisted of results from a
total of 1,322 patients, 71% of whom were
male, with a mean age of 61 (range 15 to 97) years;
362 (27.4%) had an ischemic HF cause (275 [20.8%]
with prior myocardial infarction), 1,322 had a mean
left ventricular ejection fraction (LVEF) of 37%
(range 6% to 88%), 298 (23.8%) had diabetes melli-
tus, 388 (31.0%) had hypertension, and 288 (21.8%)
had dyslipidemia. The following patients were not
submitted for inclusion in the database: patients with
end-stage renal failure requiring dialysis therapy;
patients with malignant disorders; patients with
neurogenic disorders involving the autonomic nervous
system; patients having been treated with tricyclic
antidepressant drugs or other drugs that are known
to have a sympathomimetic action and interfere
with cardiac mIBG uptake; and patients who were
scheduled to undergo any cardiac surgery (typically for
revascularization rather than device implantation).Thirteen patients (1.2%) had ICDs at the time of
mIBG imaging. Plasma B-type natriuretic peptide
(BNP) data were available for 512 patients (39%).
Cardiac mIBG imaging. Cardiac mIBG imaging
was performed using standard procedures after
administration of 111 MBq of high speciﬁc activity
123I-mIBG (commercially available in Japan, Daii-
chi Radioisotope/Fujiﬁlm RI Pharma, Tokyo,
Japan) with patients in fasting and resting condition
(8,13–19). Anterior planar mIBG images of the
chest were obtained using a gamma camera equip-
ped with a low-energy collimator 15 to 30 min
(early image) and 3 to 4 h (late image) after the
intravenous tracer injection. Cardiac 123I-mIBG
activity was quantiﬁed as HMR by manually draw-
ing regions of interest on the upper mediastinum
A B
Figure 1. ROC Analysis of Late HMR and WR
Receiver-operating characteristic (ROC) analysis of late heart-to-mediastinum ratio (HMR) and washout rate (WR) of cardiac meta-
iodobenzylguanidine (mIBG) activity, indicating that optimal cutoff values for identifying lethal events are 1.68 for late HMR (A) and
43% for WR (B).
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776and the whole cardiac region by an experienced
nuclear medicine technician who was unaware of any
clinical data. 123I-mIBG WR from the heart, based
on count differences between early and late images,
also was calculated (11).
Statistical analysis. Analysis of the combined data-
base was performed by independent statistical ex-
perts (K.N. and S.M.) without participation of theA
Figure 2. Kaplan-Meier Event-Free Curves of 2 Groups Classiﬁed by
Kaplan-Meier event-free curves of 2 groups classiﬁed by the cutoff values
rate of patients with late HMR <1.68 or WR >43% (pink) than the couother investigators. Summary values for numeric
variables are shown as mean  SD. Mean values
were compared between the 2 groups (fatal events
and survivors) using the unpaired t test, and prev-
alence values were compared using the chi-square
test. Receiver-operating characteristic (ROC) anal-
ysis was performed to determine the optimal cutoff
value of an independent signiﬁcant parameter.B
Late HMR and WR
of late HMR (1.68) and WR (43%) showing signiﬁcantly lower survival
nterparts (blue). Abbreviations as in Figure 1.
Table 2. Kaplan-Meier Analysis for Sudden Cardiac Death and Pump Failure Death at 5 Years
Late HMR ‡1.68 Late HMR <1.68 Log Rank p Value
All-cause death 10.2 31.7 88.2 <0.0001
Sudden cardiac death 2.9 8.6 24.8 <0.0001
Pump failure death 5.0 18.9 57.0 <0.0001
WR, ‡43 WR, <43 Log Rank p Value
All-cause death 28.2 13.2 53.3 <0.0001
Sudden cardiac death 9.6 2.7 25.5 <0.0001
Pump failure death 15.4 7.2 28.6 <0.0001
Values are %.
Abbreviations as in Table 1.
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777Univariate and multivariate analyses using a Cox
proportional hazards model were performed. The
multivariate model for time to all-cause mortality
was evaluated using a stepwise forward elimination
procedure and categorized variables such as age
(<30 to$80 years, 10-year unit), greater New York
Heart Association (NYHA) functional class (I/II
vs. III/IV), late HMR (<1.1 to $2.0, 0.1 unit),
LVEF (<20% to $50%, 10% unit), and BNP
(<200, 200 to 399, $400). Factors considered
included demographic data (age, sex), medical his-
tory (e.g., diabetes mellitus, hypertension), cardiacFigure 3. Kaplan-Meier Event-Free Curves of 3 Subgroups
Classiﬁed Using Late HMR
Kaplan-Meier event-free curves of 3 subgroups classiﬁed using
the mean  SD value (1.75  0.35) of late HMR in the total pop-
ulation. The event-free curves were signiﬁcantly separated into
3 categories as low-, intermediate-, and high-risk subgroups.
Abbreviation as in Figure 1.medications (e.g., angiotensin-converting enzyme
inhibitors, beta-blockers), and measured parameters
(LVEF, BNP, HMR). Factors signiﬁcant at the
p <0.05 level were retained in the model. Survival
curves of patient subgroups were created by the
Kaplan-Meier method and compared using the log-
rank test. Analyses based on sequential HMR sub-
groups were used to deﬁne thresholds for different
mortality rates to 5 years.
Models without and with inclusion of HMR
were compared using ROC curve and net reclassi-
ﬁcation improvement (NRI) methods for moreFigure 4. Kaplan-Meier Event-Free Curves of 3 Subgroups
Classiﬁed by LVEF Categories
Kaplan-Meier event-free curves of 3 subgroups classiﬁed by left
ventricular ejection fraction (LVEF) categories #35%, 36% to 49%,
and $50% showing signiﬁcantly lower survival for the patient
group with LVEF of #35% compared with that of the other
2 groups. EF ¼ ejection fraction.
A B
C
Figure 5. Kaplan-Meier Event-Free Curves According to 3 LVEF Categories
Kaplan-Meier event-free curves according to the 3 left ventricular ejection fraction (LVEF) categories: (A) LVEF of 50% or more, (B) LVEF >35%
and <50%, and (C) LVEF of #35%. The cutoff value of late heart-to-mediastinum ratio (HMR) (1.68) shows signiﬁcantly lower survival of the
subgroup with late HMR <1.68 compared with those with HMR >1.68 in each LVEF category.
Nakata et al. J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 6 , N O . 7 , 2 0 1 3
Prognosis and Cardiac Sympathetic Activity in HF J U L Y 2 0 1 3 : 7 7 2 – 8 4
778appropriate identiﬁcation of low and/or high-risk
categories. All analyses were performed using the
SAS statistical program package (JMP version 9,
SAS, Cary, North Carolina).RESULTS
During follow-up, 326 patients (24.7%) died. Of
these deaths, 263 (81%) were judged to be of cardiac
cause as part of the original studies or during the
current data review. Table 1 compares clinical back-
grounds between groups with and without lethal
events. The event group was older and more
frequently male, had a history of sustained ventricular
tachycardia (VT) and diuretic use, had greater
NYHA functional class, had greater BNP level, and
had lower LVEF. The event group less frequently had
hypertension or dyslipidemia, and used beta-blocking
agents. On mIBG imaging, the deceased group had
signiﬁcantly lower late HMR and greater WR than
the survivors. There was no signiﬁcant difference in
the prevalence of ischemic cause of HF, diabetesmellitus, or use of renin-angiotensin-aldosterone
system inhibitors between the groups.
ROC analysis identiﬁed 1.68 and 43% as optimal
thresholds of HMR and WR, respectively (Fig. 1),
for dichotomizing the population into higher- and
lower-risk patients for lethal outcomes. Patients
with late HMR <1.68 or WR >43% had signiﬁ-
cantly (p < 0.0001) lower survival rates (Fig. 2).
Likewise, the late HMR and WR values differen-
tiated the high- from the low-risk patients both for
sudden cardiac death and for pump failure death at
5 years (Table 2).
According to the mean  SD value (1.75  0.35)
of late HMR in the total population, patients were
classiﬁed into 3 subgroups that could be character-
ized as low-, intermediate-, and high-risk (Fig. 3).
Patients also could be classiﬁed into 3 subgroups
using LVEF categories: #35%, 36% to 49%, and
$50%. The subgroup with LVEF #35% had
signiﬁcantly poorer survival than the other 2 sub-
groups (Fig. 4). The late HMR threshold of 1.68
identiﬁed high-risk patients in each LVEF-
categorized subgroup (Fig. 5).
Table 3. Results of Univariate Cox Analysis for All-Cause Mortality
Chi-Square
Hazard
Ratio
95% CI
Lower–Upper p Value
Age (<30–$80 yrs, 10-yr unit) 20.76 1.23 1.12–1.34 <0.0001
Men 3.88 1.28 1.00–1.66 0.049
Ischemic cause 0.01 0.99 0.94–1.77 0.943
NYHA functional class 96.02 5.38 3.51–8.19 <0.0001
NYHA functional class (I/II vs. III/IV) 83.17 2.81 2.26–3.51 <0.0001
ACE-I and/or ARB 0.72 0.91 0.72–1.14 0.399
Beta-blockade 8.42 0.72 0.58–0.90 0.0037
Diuretics 46.17 2.50 1.89–3.38 <0.0001
LVEF (<20%–$50%, 10% unit) 40.19 0.72 0.65–0.80 <0.0001
HMR, early (<1.1–$2.0, 0.1 unit) 12.78 0.93 0.89–0.97 0.0004
HMR, late (<1.1–$2.0, 0.1 unit) 91.79 0.82 0.79–0.85 <0.0001
WR (<30%–$60%, 10% unit) 78.94 1.52 1.39–1.67 <0.0001
Diabetes mellitus 2.11 1.21 0.94–1.54 0.146
Hypertension 5.10 0.75 0.58–0.96 0.024
Dyslipidemia 13.12 0.59 0.43–0.79 0.0003
Sustained VT history 8.39 1.41 1.12–1.77 0.0038
BNP (<200, 200–399, $400) 63.00 2.76 2.12–3.63 <0.0001
ACE-I ¼ angiotensin-converting enzyme inhibitor; ARB ¼ angiotensin-receptor blocker; BNP ¼ B-type
natriuretic peptide; CI ¼ conﬁdence interval; HMR ¼ heart-to-mediastinum ratio; LVEF ¼ left ventricular
ejection fraction; NYHA ¼ New York Heart Association; VT ¼ ventricular tachycardia; WR ¼ washout rate.
Table 4. Multivariate Cox Proportional Hazards Model
for Time to All-Cause Mortality
Hazard
Ratio
95% CI
Lower–Upper p Value
Total population (N ¼ 1,320)
Age (<30–$80 yrs, 10-yr unit) 1.21 1.10–1.33 <0.0001
NYHA (I/II vs. III/IV) 2.07 1.64–2.60 <0.0001
HMR, late (<1.1–$2.0, 0.1 unit) 0.85 0.82–0.89 <0.0001
LVEF (<20%–$50%, 10% unit) 0.85 0.77–0.95 0.0029
Subpopulation with BNP data (n ¼ 512)
BNP (<200, 200–399, $400) 2.19 1.65–2.93 <0.0001
NYHA (I/II vs. III/IV) 2.05 1.41–3.05 0.0002
HMR, late (<1.1 –$2.0, 0.1 unit) 0.87 0.80–0.95 0.0011
Abbreviations as in Table 3.
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779Univariate Cox analysis identiﬁed signiﬁcant vari-
ables, including age, LVEF, BNP, and mIBG pa-
rameters (HMR and WR), listed in Table 3.
Ischemic cause, renin-angiotensin-aldosterone sys-
tem inhibitors, and diabetes mellitus were not sig-
niﬁcant. Multivariate Cox proportional hazards
analysis using categorized variables demonstrated age
(<30 to $80 years, 10-year unit), greater NYHA
functional class (I/II vs. III/IV), late HMR (<1.1 to
$2.0, 0.1 unit), and LVEF (<20% to $50%, 10%
unit) for the total population as independent signiﬁ-
cant predictors of lethal events (Table 4). When the
subpopulation with BNP was analyzed, categoric
BNP (<200, 200 to 399, $400), greater NYHA
functional class (I/II vs. III/IV), and late HMR (<1.1
to $2.0, 0.1 unit) were identiﬁed to be signiﬁcant,
but LVEF (<20% to $50%, 10% unit) was not.
All-cause mortality progressively decreased with
increasing HMR. All-cause mortality rates at 1 year,
2 years, and 5 years for the total population were
5.6%, 11.3%, and 19.7%, respectively (Fig. 6).
When late HMR was <1.7, mortality rates at these
3 times were greater than the average, whereas those
with HMR >1.7 had below average mortality rates,
conﬁrming the ﬁndings of the earlier ROC analysis
(HMR threshold 1.68). For 5-year mortality, pa-
tients with HMR #1.2 had an annual death rate
>7%, whereas patients with HMR $2.0 had an
annual death rate <2%.
Table 5 shows the results of NRI analysis of the
models using age (decile), LVEF (decile), and
NYHA functional class (I/II vs. III/IV) with and
without late HMR data at 3 5-year mortality
categories of <10%, 10% to 30%, and >30%.
Compared with the baseline model without HMR,
the model with HMR had net gains in reclassiﬁ-
cation of 0.073 for patients who died (p ¼ 0.0415),
0.102 for surviving patients (p < 0.0001), and
NRI ¼ 0.175 (p < 0.0001).
D I SCUSS ION
The present study using multiple cohort studies
demonstrated the independent prognostic value of
altered cardiac sympathetic function as assessed
by categorical and numeric HMR data from cardiac
mIBG imaging. Compared with earlier inves-
tigations (6–11), including the ADMIRE-HF
(AdreView Myocardial Imaging for Risk Evalua-
tion in Heart Failure) study, the present results
showed the long-term efﬁcacy of risk assessment by
HMR for more than 10 years. The results derived
from a large number of patients not only support
previous mIBG data, but also strengthen the valueof quantitative mIBG markers to identify all-cause
mortality risk in patients with HF. The present
data also reﬂect the consistent, high-quality imaging
procedures using high speciﬁc activity 123I-mIBG in
the prospective cohort studies. More important, the
results suggest that the HMR could be used to
deﬁne suitable thresholds for high and low risk to
facilitate therapeutic decision making.
Patient-level pooled analysis. Unlike a previous
mIBG meta-analysis, which only included calcula-
tions based on published aggregate imaging and
Table 5. Net Reclass
of 10% and 30% per
Model Without HM
Frequency and Row
Patients with events
<10%
10%–30%
>30%
Total
Patients without even
<10%
10%–30%
>30%
Total
Values are n (%) or n.
Abbreviation as in Table
Figure 6. All-Cause Mortality Rates at 1 Year, 2 Years, and
5 Years in the 11 HMR-Categorized Groups
All-cause mortality rates at 1 year (closed circles), 2 years
(open diamonds), and 5 years (closed squares) in the 11 HMR-
categorized groups; total population mortality rates (dotted lines)
are 5.6% at 1 year, 11.3% at 2 years, and 19.7% at 5 years. For
late HMR <1.7, mortality rates tended to exceed the population
mortality rates at 1, 2, and 5 years, indicating high-risk patients.
Abbreviation as in Figure 1.
Nakata et al. J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 6 , N O . 7 , 2 0 1 3
Prognosis and Cardiac Sympathetic Activity in HF J U L Y 2 0 1 3 : 7 7 2 – 8 4
780outcome results (12), this study involved collection
of the individual data records for each patient
with HF, thereby permitting detailed analyses of the
full combined population and selected relevant
subpopulations. A particular strength of the present
study was the use of multiple different analysis
techniques, including ROC curve, Kaplan-Meier
survival, Cox proportional hazards, and NRI.
Multivariate Cox analysis demonstrated indepen-
dent prognostic value for mIBG imaging ﬁndings
beyond that of demographic and medical history
variables. NRI conﬁrmed appropriate reclassiﬁcationiﬁcation Analysis for All-Cause Mortality at Risk Levels
5 Years
R Model With HMR
% <10% 10%–30% >30% Total
10 (34.50) 19 (65.50) 0 (0.00) 29
11 (8.60) 88 (68.80) 29 (22.70) 128
0 (0.00) 19 (21.10) 71 (78.90) 90
21 (8.50) 126 (51.00) 100 (40.50) 247
ts
235 (82.20) 51 (17.80) 0 (0.00) 286
160 (25.20) 415 (65.30) 61 (9.60) 636
0 (0.00) 61 (40.70) 89 (59.30) 150
395 (36.80) 527 (49.20) 150 (14.00) 1,072
1.of patients who did and did not have lethal
events. Examined from these multiple statistical
perspectives, the merged data from the participating
sites provided consistent evidence of efﬁcacy for
cardiac mIBG imaging equivalent to that typically
obtained from a multicenter prospective trial. A
further measure of the success of the analyses was the
consistency of the results for subsets, including those
based on different LVEF ranges. Despite the ex-
pected limitations inherent in aggregating data
originally collected over a 20-year period, the con-
sistency of the results provides validation of the
methods used in performance of this pooled patient-
level analysis.
Mechanisms of impaired cardiac sympathetic
innervation. Cardiac sympathetic imaging can help
in understanding the pathophysiological and prog-
nostic implications of alterations of cardiac sympa-
thetic nerve function and innervation in HF. Given
that abnormalities of cardiac sympathetic innerva-
tion are common in most forms of heart disease,
including ischemic and nonischemic causes (6–9,
21,22), and medications affecting this system
(particularly beta-blockers) are among the most
effective therapies for patients with HF and is-
chemic heart disease, a quantitative assessment of
this system should have obvious value as an addi-
tional piece of relevant medical information. Al-
though the mIBG imaging technique has been
readily available in Japan for 2 decades, the new
insights provided by this pooled analysis should
expand understanding of the importance of the
sympathetic nerve ﬁndings. In the same way that
assessment of myocardial perfusion provides func-
tional insights to supplement the information
about coronary artery disease provided by angio-
graphic procedures, assessment of myocardial sym-
pathetic innervation augments the morphological
and mechanical indices on left ventricular dimen-
sions and systolic and diastolic function provided
by methods such as echocardiography and cardiac
magnetic resonance.
Several investigations have shown that impaired
cardiac mIBG activity can improve in response to
currentmedical management using beta-adrenoceptor
blockers and inhibitors of the renin-angiotensin-
aldosterone system in selected patients (23,24).
Therefore, this imaging technique can help tomonitor
response to therapy and is also likely to predict the
effectiveness of such drug treatment and non-
pharmacological device therapy in patients with HF
(25–28). However, decreased late cardiac mIBG ac-
tivity and increased WR can reﬂect the aggregate
effect of a number of processes that cannot be
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781individually assessed in vivo, such as reduced number
of sympathetic nerve terminals, decreased tyrosine
hydroxylase activity, decreased function of NE and
vesicular monoamine transporters, and increased
neuronal stimulation with increased NE turnover.
Impaired sympathetic pre-synaptic activity in
conjunction with excess and long-lasting activation of
central excitatory inputs not only limits compensatory
action to maintain cardiac inotropy, but also induces
dysregulation of post-synaptic adrenoceptor signal
transduction, potentially producing denervation su-
persensitivity that may contribute to lethal arrhyth-
mogenicity in failing hearts (29).
Impact on clinical management of patients with HF.
Precise risk stratiﬁcation of patients with HF can
contribute to implementation of prophylacticmedical
therapy against lethal events and appropriate selec-
tion of candidates who can beneﬁt most from non-
pharmacological device therapy using ICDs (26–28)
and/or cardiac resynchronization therapy. LVEF
provides little prognostic information for the one-
third to one-half of patients with HF with pre-
served LV systolic function, and the prognostic
limitations of LVEF for the prediction of sudden
cardiac/arrhythmic death have been noted (30). In
this study, the prognostic value of LVEFwas reduced
when other powerful prognosis indicators such as
BNP and cardiac mIBG activity were available,
whereas the prognostic value of cardiacmIBG activity
was successfully demonstrated in patients with HF
with reduced and normal LVEF. It is unlikely but
needed in the foreseeable future to establish speciﬁc
treatments for impaired cardiac sympathetic inner-
vation independently of LVEF. Nevertheless, iden-
tiﬁcation of neuronal deﬁciencies using mIBG
neuroimaging should contribute tomore effective use
of currently available therapies and therefore better
outcomes for patients with HF.
The value of accurate risk stratiﬁcation should be
greatest for patients identiﬁed as being of high or
low risk for adverse outcomes. In that regard, pa-
tients with preserved myocardial sympathetic
innervation (HMR $1.95) had an annual death
rate <2%, whereas those with substantially reduced
innervation (HMR <1.25) had an annual death
rate >7%, demonstrating the degree of difference in
prognosis that can be determined with mIBG im-
aging. The important observation is that user-
deﬁned high and low event rate HMR thresholds
can be developed using data appropriate for speci-
ﬁed populations. For example, in the Japanese
population, an HMR threshold of 1.15 deﬁned an
even higher annual mortality rate of >10%. Given
that patients with HF are considered for manydrugs and invasive and expensive device treatments,
there is a great need for ﬂexible prognostic pro-
cedures to identify the highest- and lowest-risk
patient groups.
Prediction of mode of death is another important
clinical issue in HF management. The presented
mIBG results did not predict mode of death, but
rather identiﬁed high and low risk for each mode of
death using late HMR or WR, suggesting the
mechanistic relevance of impaired cardiac innerva-
tion and inappropriately augmented cardiac sym-
pathetic stimulation to HF progression and sudden
cardiac events. However, the present results cannot
be used to indicate which mode of death will
affect a particular high-risk patient. Sudden death
per se is an outcome resulting from multifactorial
pathologies and several triggers that could be
modulated by interaction in various clinical condi-
tions, including diabetic state, kidney function, and
anemia (31). Hemodynamic instability enhances
tachyarrhythmias via augmentations of afferent and
efferent autonomic neuronal regulation and the
renin-angiotensin-aldosterone system, leading to
ischemia and myocyte injury, all of which in turn
produce a vicious cycle resulting in pump failure and
lethal arrhythmic events.
The present study did not directly address the in-
ﬂuence of ischemia on arrhythmogenicity as a
mechanismof sudden death.However, the possibility
is supported by our previous ﬁndings (28) that
impairment of myocardial perfusion is related to le-
thal arrhythmic events/ICD shocks independently of
and in addition to altered cardiac sympathetic
innervation. From the previous (26–28) and the
present ﬁndings, further prospective large-cohort
investigations are justiﬁed for more precise identiﬁ-
cation of patients with HF at low or high probability
of sudden cardiac death and for establishing more
appropriate indication for prophylactic or therapeutic
use of ICDs in patient populations categorized
by LVEF and background cardiac diseases.
Study limitations. Because only baseline data
collected at the time of the original studies were
available, the individual datasets did not always
include complete records of patient demographics,
medical history, concomitant medications, and
proﬁles of excluded patients before enrollment in
each original database. Likewise, because of the age
of some studies, more recently introduced bio-
markers such as BNP were only available for a
minority (512 [39%]) of the 1,322 patients. A
limitation of the VT classiﬁcation was that history
of “sustained” VT was independently conﬁrmed at
each institution, and at the time of mIBG imaging,
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782few patients (n ¼ 13) had ICDs that would have
provided more accurate documentation of rhythm
disturbances. There is also a lack of sufﬁcient
information on ICD therapy during long-term
follow-up, which could affect the outcome
analyses.
The prevalence of ischemic HF cause was as
much as 50% lower than in many western countries
(32), but this is representative of the 25% to 35%
prevalence of ischemic cause in Japanese patients
with HF reported in many cohorts. Nevertheless,
the proportion of patients with ischemic HF was
nearly identical (27%) in the dead and surviving
groups, and HF cause was not signiﬁcant in the
multivariate analyses. The high proportion of pa-
tients with nonischemic cardiomyopathy also may
have contributed to the lower than expected mor-
tality rate compared with other clinical HF trials
(32). Overall, the results are consistent with our
previous study (13) and a recent prospective trial
(11) that demonstrated comparable prognostic
value of cardiac mIBG activity in patients with
ischemic HF cause and patients with nonischemic
HF cause.
Because almost all the original studies were
observational, the new analyses can provide infor-
mation about prognosis but not the therapeutic
implications of these observations. The consistency
of the aggregate results does support the desir-
ability of a prospective interventional study to
establish appropriate therapeutic strategies in pa-
tients with HF identiﬁed to be at greatest risk for
lethal events by cardiac mIBG imaging. However,
even without such a study, the results of the pre-
sent analyses, in conjunction with those of the
recent prospective mIBG trial (11), indicate that
HMR values from cardiac mIBG imaging can
identify patients with HF who might not be
identiﬁed from conventional clinical and laboratory
assessments as requiring more aggressive or more
conservative treatment.
As presented in previous publications and in this
study, cardiac mIBG parameters (delayed HMR and
WR) have been used to monitor patient outcome
and response to medical treatment. However, HMR
has not been standardized among publications from
various institutions and countries, primarily because
of patient-based and methodology-based reasons
(33,34). Fortunately, in this study consisting of
multiple Japanese prospective cohorts, imaging
protocols (including collimator used), dose, and
speciﬁc activity of 123I-mIBG were nearly uniform(8,11,13–19). Nevertheless, the exact numeric
HMR values cannot be readily applied to studies
performed in other geographies and using other
methodologies. Finally, a cost–beneﬁt analysis is
needed to identify speciﬁc patients in whom cardiac
mIBG imaging in combination with conventional
clinical and laboratory information would be most
beneﬁcial.
CONCLUS IONS
A patient-level pooled analysis combining 6 pro-
spectively obtained HF databases, with 1,322 Jap-
anese patients, clearly demonstrated the long-term
prognostic value of altered cardiac sympathetic
function as assessed by cardiac mIBG imaging. The
continuous numeric and categorical assessment of
cardiac mIBG activity using HMR provides infor-
mation on the probability of survival in patients with
HF independently of plasma BNP level and LVEF.
By using the HMR values, the cardiologist can
deﬁne the particular level of risk at which speciﬁc
therapeutic interventions are deemed appropriate or
unnecessary.
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